ARZERRA 20mg / ml perfusive solution concentrate medication leaflet

L01FA02 • ofatumumab • Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Cd20 (clusters of differentiation 20) inhibitors

Ofatumumab is a monoclonal antibody used for the treatment of relapsing multiple sclerosis and chronic lymphocytic leukemia. It works by targeting the CD20 protein on the surface of B lymphocytes, thereby destroying these cells and reducing disease activity.

The medication is administered via subcutaneous injection or intravenous infusion, as directed by a doctor. The dosage and frequency of administration are adjusted based on the condition being treated and the patient's response.

Patients should be monitored for potential side effects, such as injection site reactions, infections, or fever. It is important to inform the doctor of any unusual symptoms.

Common side effects include injection site reactions, upper respiratory tract infections, fever, and headaches. In rare cases, severe reactions such as serious infections or allergic reactions may occur. Patients should be informed of these risks before starting treatment.